Fortrea HoldingsFTRE -0.06%66 PB Ratio is 3.17 as of Jun. 29, 2026, which is 109% above its 10-year median of 1.52. GuruFocus rates FTRE with a GF Score™ of 66/100 and a GF Value™ of $18.26 (Fairly Valued). The stock has 7 warning signs investors should review. Among 1,232 Biotechnology companies, Fortrea Holdings ranks worse than 55.03% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-29), Fortrea Holdings's share price is $17.64. Fortrea Holdings's Book Value per Share for the quarter that ended in Mar. 2026 was $5.56. Hence, Fortrea Holdings's PB Ratio of today is 3.17.
Warning Sign:
Fortrea Holdings Inc stock PB Ratio (=3.18) is close to 5-year high of 3.18.
The historical rank and industry rank for Fortrea Holdings's PB Ratio or its related term are showing as below:
FTRE'
s PB Ratio Range Over the Past 10 Years
Min: 0.43 Med: 1.52 Max: 3.2
Current: 3.17
During the past 6 years, Fortrea Holdings's highest PB Ratio was 3.20. The lowest was 0.43. And the median was 1.52.
FTRE's PB Ratio is ranked worse than 55.03% of 1232
companies
in the Biotechnology industry
Industry Median: 2.835
vs FTRE: 3.17
During the past 12 months, Fortrea Holdings's average Book Value Per Share Growth Rate was -41.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -45.60% per year.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Fortrea Holdings was -25.50% per year. The lowest was -45.60% per year. And the median was -35.55% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Fortrea Holdings PB Ratio Related Terms
Fortrea Holdings PB Ratio Historical Data
* Premium members only.
The historical data trend for Fortrea Holdings's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Fortrea Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fortrea Holdings PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fortrea Holdings's PB Ratio distribution charts can be found below:
* The bar in red indicates where Fortrea Holdings's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Fortrea Holdings (FTRE) has a PB Ratio of 3.17 as of Jun. 29, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Fortrea Holdings and its competitors. This is 109% above median its historical median of 1.52. Over the past decade, Fortrea Holdings' PB Ratio has ranged from 0.43 to 3.20. According to the industry distribution chart, Fortrea Holdings ranks #678 out of 1232 companies in the Biotechnology industry, placing it in the top 55%.
Is Fortrea Holdings' PB Ratio too high?
Fortrea Holdings' current PB Ratio of 3.17 is 109% above median its 10-year median of 1.52. Over the past 10 years, this metric has ranged from a low of 0.43 to a high of 3.20. The Biotechnology industry median PB Ratio is 2.84. Fortrea Holdings' value of 3.17 is 11.8% above this industry median. Based on the distribution chart, Fortrea Holdings ranks #678 out of 1232 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Fortrea Holdings has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fortrea Holdings' PB Ratio compare to SEPN and MLTX?
According to the Biotechnology industry distribution chart, Fortrea Holdings ranks #678 out of 1232 companies for PB Ratio. This places Fortrea Holdings in the lower half of its industry. The industry median PB Ratio is 2.84. Fortrea Holdings' value of 3.17 is 11.8% above this benchmark. Historically, Fortrea Holdings' own PB Ratio has ranged from 0.43 to 3.20 over the past decade. While the company's 10-year median is 1.52 vs. the industry median of 2.84, Fortrea Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.84, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fortrea Holdings's current PB Ratio of 3.17 is 11.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Fortrea Holdings and its competitors. For the Biotechnology industry, the median PB Ratio is 2.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fortrea Holdings's current PB Ratio is 3.17, which is 109% above median its own 10-year median of 1.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fortrea Holdings stock overvalued right now?
Based on GuruFocus' analysis, Fortrea Holdings (FTRE) is currently considered Fairly Valued. The stock's GF Value™ is $18.26, compared to a current price of $17.64 — trading 3.4% below its estimated fair value. The current PB Ratio is 3.17, which is 109% above median its 10-year median of 1.52 and 11.8% above the Biotechnology industry median of 2.84. Fortrea Holdings' overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Fortrea Holdings (FTRE), the current PB Ratio is 3.17 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fortrea Holdings (FTRE) Overvalued in 2026?
Based on GuruFocus' analysis, Fortrea Holdings stock appears to be undervalued.
The current stock price of $17.64 is trading 3.4% below its estimated GF Value™ of $18.26.
GuruFocus considers Fortrea Holdings to be Fairly Valued.
Key valuation signals for FTRE:
PB Ratio: 3.17 (109% above median its 10-year median of 1.52)
GF Value™: $18.26 vs. price of $17.64 (3.4% below fair value)
Industry Position: 11.8% above the Biotechnology median (#678 of 1232)
No single metric tells the full story. See the FTRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.
66GF Score
Get the complete analysis for FTRE
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FTRE has been successfully added to your 
